The Antibody Society

the official website of the antibody society

An international non-profit supporting antibody-related research and development.

You are here: Home / Archives for antibody engineering

The Huston Antibody Science Talent Award competition is open!

by

The James S. Huston Antibody Science Talent Award is sponsored by The Antibody Society to recognize and encourage upcoming scientists in the field of Antibody Engineering and Therapeutics. Early career research scientists who have received an advanced degree (Ph.D., M.D., or equivalent) within the past ten (10) years are eligible for the Award. The scientist is recognized for making important contributions to the antibody field and/or the dissemination of antibody knowledge. The recipient will be invited to give a lecture on their work, which will be made available on-line on The Antibody Society’s website, and to give a lecture at the Antibody Engineering & Therapeutics conference in December 2022.

The award includes: international recognition of the scientist’s accomplishments, a $1500 USD prize, and travel costs and registration fees to attend the annual Antibody Engineering & Therapeutics conference in San Diego, California.

The nomination process details are here. The deadline for submission is September 15, 2022.

The Society has selected mAbs as its Official Journal!

by

The Antibody Society is pleased to announce that it has partnered with Taylor & Francis, a leading research publisher, to make mAbs the Society’s Official Journal. mAbs is a multidisciplinary, open access journal dedicated to the art and science of antibody research and development. The journal has a strong scientific and medical focus but serves a broad readership, including specialists in technology transfer, legal issues, investment, and the regulation of therapeutics.

Since 2009, mAbs has published high quality reports, reviews, and perspective articles covering a range of antibody R&D topics, including:

  • Engineering and selection of antibody therapeutics, including antibody-drug conjugates, multispecific antibodies, and single-domain antibodies
  • Machine learning and artificial intelligence applications
  • Non-clinical studies of antibodies, such as mechanism of action studies, safety, and efficacy studies in animals
  • Manufacturing and formulation
  • Regulatory review of antibody therapeutics
  • Post-approval topics, such as markets

The journal’s 2021 Impact Factor is 6.440 and, in total, articles are downloaded at a rate of over 1 million per year. Articles in the current volume (14) can be found here.

Members of The Antibody Society receive a 10% discount on article publication charges using their member code.

We look forward to a productive partnership with Taylor & Francis.

Thanks to all who participated in Antibody Engineering & Therapeutics Europe!

by

Another very successful Antibody Engineering & Therapeutics Europe has concluded!

The Antibody Society thanks all the volunteers who helped at the booth:

 

  • Demelza Willemsz (Genmab)
  • Thomas Wesselink (Genmab)
  • Chalana Zilvold – van den Oever (Genmab)
  • Charlotte Berendsen (Genmab)
  • Lisa King (Amsterdam UMC)
  • Milon de Jong (Amsterdam UMC)

In addition to Thomas, Milon and Lisa, Kerry Chester (Board of Directors member), Janine Schuurman (Society Vice President) and Sally Ward (Society President) appear in the image above.

We hope to see you in Amsterdam in June 2023 for the next Antibody Engineering & Therapeutics Europe.

Join us on April 28th for our webinar on Fc silencing techniques!

by

Registration is open!

Thursday April 28, 2022, 11am ET

Speaker: Ian Wilkinson, PhD

Antibodies are nature’s pro-drugs, wonderfully evolved to target pathogens and activate immune systems. For certain indications where ADCC or CDC are required this is ideal, but for many other applications activation of inflammatory responses is unnecessary and potentially highly undesirable. In these situations silenced antibodies with either naturally low effector function or engineered Fc domains are the preferred option. However, many of the commonly used options in the clinic, such as IgG4, LALA or aglycosylation, are widely reported to still have residual Fc receptor binding and cytokine activation in patients.

This presentation will describe the first thorough comparison of most of the generic and proprietary Fc silencing mutations, demonstrating that all previously reported variants show residual binding to Fc receptors. It will also describe the discovery of a novel set of mutations, known as STR, that show no detectable binding to Fcγ receptors and do not elicit inflammatory cytokine responses. Meanwhile, immunogenicity, stability and PK are unaffected. This totally silenced variant has the potential to improve the safety and efficacy of therapeutic antibodies and Fc fusion proteins.

Career Shorts Ep 2 – Dr Nimish Gera

by

After the launch of our new Career Shorts series last week, we are proud to release our second episode with Dr Nimish Gera, Head of Biologics at Mythic Therapeutics! Check out our new episode via our new YouTube channel using the link below.

Career Shorts Ep 2: https://youtu.be/kOpuBxNdS5A

 

Our previous episode (Ep 1 with Dr Li Zhou): https://youtu.be/Y9xtGRLQaSM
Career shorts webpage: https://www.antibodysociety.org/career-shorts/

About Career shorts:

In this series, we talk to scientists and individuals working within the world of antibodies about the experiences that have shaped their careers and have got them to where they are today. Our goal by sharing their experiences and advice is to empower the next generation of scientists and leaders working in this field and beyond to make confident and empowered decisions.